Here’s why the Recce (ASX:RCE) share price has fallen 7% today

Shareholders in Recce Pharmaceuticals Ltd (ASX: RCE) have been hitting the sell button following the release of its quarterly update.

| More on:

Source: Getty Images

Shareholders in Recce Pharmaceuticals Ltd (ASX: RCE) have been hitting the sell button today following the release of its quarterly update.

At the time of writing, the Recce share price is trading 7.59% lower at $1.10. This represents a decline of 40% since the price reached an all-time high of $1.87 last month.

Let’s see what Recce achieved for the quarter.

Trading update

For the period ending September 30, Recce reported a cash balance of $25.6 million due to a successful capital raise. Cash out-flows from operations came to $3.3 million with $2.5 million invested in research and development.

The company received a $37,508 grant as part of the Entrepreneurs’ Program run by the Department of Industry, Science, Energy and Resources. The funds are expected to be put towards its Recce 327 SARS-CoV-2 antiviral screening program.

The company said it was well-funded to advance its clinical and commercial programs to date.

Operational highlights

Recce briefly touched on its operational developments over the last quarter, highlighting key achievements.

Recce 327

The phase I clinical study of its flagship drug, Recce 327 is currently being trialled at South Australia’s CMAX Clinical Research. The company said that the program was progressing well with significant volumes of Recce 327 and placebos being produced. The phase I study aims to assess the safety and tolerability of Recce 327 in healthy patients as a single ascending dose.

SARS-CoV-2 International Studies

In addition to the clinical trial, University of Tennessee researchers evaluated the Recce 327 and Recce 529 compounds. Medical professionals are looking into the viability that the company’s products could assist recovery in the respiratory illness.

In response, Recce plans to test the compounds on animals, with data available at the end of the calendar year.

Recce 435

The company has formulated a new oral antibiotic to fight against Helicobacter pylori (H. pylori) bacteria. The Murdoch Children’s Research Institute entered an agreement with Recce to conduct a range of pre-clinical studies assessing Recce 435. The program is being carried out by the Mucosal Immunology Group at the MCRI, Royal Children’s Hospital in Melbourne.

Management changes

During the reporting period, Recce expanded its management and advisory teams with a number of new appointments.

Dr Alan W Dunton joined the board as an independent non-executive director and member of the company’s audit & risk/remuneration & nomination committees. Dr Dunton has previously led clinical research development teams through the regulatory review and commercialisation process.

Professor Phillip Sutton will lead the team working on the Recce 435’s helicobacter pylori stomach development program. Mr Sutton has more than 30 years’ experience of research, having served as the former head of immunology at CSL Limited (ASX: CSL).

And lastly, Mr James Graham was appointed CEO and Michele Dilizia as chief scientific officer. Both have been with the company since inception and will continue their roles as members of the board.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of August 16th 2021

Aaron Teboneras owns shares of CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News